HELX P&L Curve

Franklin Genomic Advancements ETF (HELX) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $34.0M, listed on CBOE, carrying a beta of 0.98 to the broader market. This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. public since 2020-02-27.

A profit/loss curve charts the theoretical gain or loss of an options position across a range of underlying prices. It helps traders visualize risk, identify breakeven points, and compare strategies before committing capital.

Exchange
CBOE
Sector
Financial Services
Industry
Asset Management
Market Cap
$34.0M
IPO Date
2020-02-27
Beta
0.98

As of Nov 13, 2026, the Franklin Genomic Advancements ETF spot price is $42.01; P&L scenarios can be constructed from the options chain. Payoff diagrams should be rebuilt from the live options chain; the preceding values are illustrative and assume a single at-the-money straddle for reference.